Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes - Wikidata - wikimedia - TriplyDB

Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes

Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes

http://www.wikidata.org/entity/Q37207913

about

High levels of IgM against methylglyoxal-modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes.Modified Lipoproteins in Diabetic Retinopathy: A Local Action in the Retina B lymphocytes as emerging mediators of insulin resistance.Circulating autoantibodies against the apolipoprotein B-100 peptides p45 and p210 in relation to the occurrence of carotid plaques in 64-year-old women.Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for intervention Detection of circulating IgG antibodies to apolipoprotein B100 in acute myocardial infarction.Prediction of diabetic retinopathy: role of oxidative stress and relevance of apoptotic biomarkers.Extravascular modified lipoproteins: a role in the propagation of diabetic retinopathy in a mouse model of type 1 diabetes.Proteomic Insight Reveals Elevated Levels of Albumin in Circulating Immune Complexes in Diabetic Plasma.Elevated Levels of Plasma IgA Autoantibodies against Oxidized LDL Found in Proliferative Diabetic Retinopathy but Not in Nonproliferative Retinopathy Immune complex formation in human diabetic retina enhances toxicity of oxidized LDL towards retinal capillary pericytes B cells as under-appreciated mediators of non-auto-immune inflammatory disease.Atherosclerosis, diabetes and lipoproteins.State of the union between metabolism and the immune system in type 2 diabetes.Targeting inflammation in cardiovascular diseases. still a neglected field?Vaccines against atherosclerosis.B Lymphocytes in obesity-related adipose tissue inflammation and insulin resistance.Obesity modulates the immune response to oxidized LDL in hypertensive patients.Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus.Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD.

P2860

Q33930928-2BAD9805-3989-44C4-94C9-BF7C4BA34A1B Q33942486-20542DF9-8F97-4844-88B1-B1A1CCA3A52F Q33942560-612BE4CD-7528-426C-BDDE-A4740D347762 Q35175305-CF5A0D3B-ECE3-4A22-91A0-75F5A26C6883 Q35998510-DD5892F2-11F5-4AE5-9E9C-53E506BECE4A Q36042620-DD5A8BE4-F65D-4BBA-9131-28263116E83E Q36117585-0E879EE6-CC53-4C75-995B-28E06480BF0E Q37143813-BC22C1BE-0795-40DC-A4A1-C882DD3C642A Q37372290-9C68D1CD-F091-4498-823B-4CA577286663 Q37549608-41B47284-338D-445B-B97D-6E3989C583C2 Q37716355-30417795-07EB-4605-8B4F-9E7FD8BFD088 Q37728724-5718506F-5ED1-490A-A4D4-45ADAD63AEB7 Q37770113-B5FBD354-1D7D-48C4-8112-86498E36048F Q37851349-2374A27E-6573-4487-A615-0E794962C655 Q37925018-917A2BAD-FE15-4326-896C-A13D5009971F Q38089941-37C66EE0-7D92-4BCB-A849-D2B7A5E11D2C Q38152732-DC342CA8-2ACB-4F4B-9672-F38B783420C5 Q38316537-5732FB8B-1ED0-470F-B42A-BA5C59955A61 Q49072554-8C87467E-13CA-4A7B-9D64-DBB2BCB91BC4 Q49409256-5D861696-34A4-4EAA-B540-B26677562136

P2860

Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes

http://www.wikidata.org/entity/Q37207913

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Associations between autoantib ...... patients with type 2 diabetes

@en

Associations between autoantib ...... patients with type 2 diabetes.

@nl

type

label

Associations between autoantib ...... patients with type 2 diabetes

@en

Associations between autoantib ...... patients with type 2 diabetes.

@nl

prefLabel

Associations between autoantib ...... patients with type 2 diabetes

@en

Associations between autoantib ...... patients with type 2 diabetes.

@nl

P1433

Q37207913-75EF8CDE-8116-4C31-AEF7-131A613F1079

P1476

Q37207913-5B8FAB9B-0C2C-4C57-ACB6-CD4A0E7A90BA

P2093

Q37207913-1D2F84DC-9887-4C65-8B47-E80D8CB2CCF2

Q37207913-28979A80-192E-4A0F-A6E4-7AFAF10C4E44

Q37207913-329FF352-4502-4A49-A0AB-F8264183DB46

Q37207913-469EC642-CEF7-49E3-B258-5FE28B2F1CC5

Q37207913-6E874A9A-8283-4F31-BDFA-3E020DE6729C

Q37207913-99463259-58CE-4919-8F5C-367484635AE3

Q37207913-9C79E286-FB7D-4D51-9D30-39D3030038F9

Q37207913-C9EFCE63-2ED3-47A5-BEFF-3D8E2027888C

Q37207913-F3BDBE57-DC59-4CFD-A1BF-B8C0EE22D5DD

P2860

Q37207913-0B09DF04-2CB1-4C1A-B68D-F9A439ECE782

Q37207913-0CE2573A-D69E-4A27-BFF4-2DE5D2FB6060

Q37207913-139802B8-B040-4D76-874E-CD52ECA4B69A

Q37207913-18AF4C7D-89B2-4251-A750-97431CE7C60F

Q37207913-240B1F17-AD6C-4446-83E3-897BF97375DC

Q37207913-24F363E3-D7E5-4C57-9AF1-0A940DDB0D26

Q37207913-364AAA4D-5A70-4AC1-AE5C-5CEB7A0FE4B1

Q37207913-3A86AF0F-55DD-4BCB-A012-107531B66B12

Q37207913-60986E85-2636-4087-AB18-E4CD728FA734

Q37207913-61932C09-A55F-4168-9B20-42C3CBD4FB62

P2888

Q37207913-094E1C69-0BF8-4FF0-A7F6-148966CA8A85

P304

Q37207913-D22B1E1B-06C5-4E84-BC81-3FB3C9FBDBD2

P31

Q37207913-E1AF9E78-90E6-4774-B4DD-3F9272915F6C

P356

Q37207913-22FC0003-5B7E-4180-9ECF-A1603845987C

P433

Q37207913-D9382895-E3B4-442B-83E8-6D4483FA6851

P478

Q37207913-81321D54-E735-4705-996D-47E21A756A46

P577

Q37207913-B3CAEAE4-950E-4716-AEED-1228E8569976

P5875

Q37207913-A71D3E77-2BF4-49CF-B424-6938FF88C3E5

P698

Q37207913-5E501FC3-28A3-495A-962B-C5D585EC4B1A

P921

Q37207913-4EFA7252-4BF6-4B48-B1C8-C368E49A815B

Q37207913-E5F7B944-1DC7-422D-BB65-DA800E79E10A

P932

Q37207913-8162C688-56E7-478E-91C8-2B5B3E4E5ECD

P356

S00125-009-1377-9

P1433

P1476

Associations between autoantib ...... patients with type 2 diabetes

@en

P2093

A Lahiri

http://www.w3.org/2001/XMLSchema#string

D Hopkins

http://www.w3.org/2001/XMLSchema#string

D V Anand

http://www.w3.org/2001/XMLSchema#string

E Bengtsson

http://www.w3.org/2001/XMLSchema#string

G N Fredrikson

http://www.w3.org/2001/XMLSchema#string

J Nilsson

http://www.w3.org/2001/XMLSchema#string

P K Shah

http://www.w3.org/2001/XMLSchema#string

R Alm

http://www.w3.org/2001/XMLSchema#string

R Corder

http://www.w3.org/2001/XMLSchema#string

P2860

Atherosclerosis. the road ahead

The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy?

Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease.

Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences.

LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis.

Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis.

Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality.

Immunomodulation of atherosclerosis: implications for vaccine development.

Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis

Innate and acquired immunity in atherogenesis.

P2888

s00125-009-1377-9

P304

1426-1433

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00125-009-1377-9

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24433852

http://www.w3.org/2001/XMLSchema#string

P698

19448981

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

2688611

http://www.w3.org/2001/XMLSchema#string